Allakos (NASDAQ:ALLK) Rating Reiterated by Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their neutral rating on shares of Allakos (NASDAQ:ALLKFree Report) in a research note issued to investors on Thursday morning, Benzinga reports.

Allakos Price Performance

Allakos stock opened at $1.11 on Thursday. The stock’s 50 day moving average is $1.20 and its 200 day moving average is $1.58. Allakos has a one year low of $0.98 and a one year high of $5.64. The firm has a market cap of $98.28 million, a P/E ratio of -0.45 and a beta of 0.93.

Allakos (NASDAQ:ALLKGet Free Report) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.09). Equities analysts anticipate that Allakos will post -1.24 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Allakos

Hedge funds have recently added to or reduced their stakes in the business. Opaleye Management Inc. bought a new position in shares of Allakos during the 1st quarter worth about $3,068,000. Ikarian Capital LLC raised its stake in Allakos by 293.4% during the 1st quarter. Ikarian Capital LLC now owns 932,675 shares of the company’s stock worth $1,175,000 after buying an additional 695,619 shares during the period. BVF Inc. IL boosted its holdings in Allakos by 93.5% in the first quarter. BVF Inc. IL now owns 16,552,417 shares of the company’s stock worth $20,856,000 after acquiring an additional 8,000,000 shares in the last quarter. Platinum Investment Management Ltd. grew its stake in Allakos by 84.6% in the first quarter. Platinum Investment Management Ltd. now owns 1,172,061 shares of the company’s stock valued at $1,477,000 after acquiring an additional 537,038 shares during the period. Finally, Acadian Asset Management LLC increased its holdings in shares of Allakos by 1,753.1% during the first quarter. Acadian Asset Management LLC now owns 1,331,639 shares of the company’s stock valued at $1,677,000 after acquiring an additional 1,259,778 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors.

About Allakos

(Get Free Report)

Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.

Read More

Analyst Recommendations for Allakos (NASDAQ:ALLK)

Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.